Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome
| Autor: | Tetsu Shinkai, Tetsuro Kodama, Takayuki Kuriyama, Noriharu Shijubo, Takahiko Sugiura, Masanori Sakurai, Haruo Iguchi, Masaaki Kawahara, Ken Yamaguchi, Kiyoshi Mori |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Drug
Male Cancer Research medicine.medical_specialty Lung Neoplasms Time Factors medicine.drug_class media_common.quotation_subject medicine.medical_treatment Uterine Cervical Neoplasms Antineoplastic Agents Pharmacology Gastroenterology Inappropriate ADH Syndrome Internal medicine Arginine vasopressin receptor 2 medicine Humans Radiology Nuclear Medicine and imaging Carcinoma Small Cell media_common Mozavaptan Aged Chemotherapy business.industry Palliative Care Sodium General Medicine Antidiuretic Hormone Receptor Antagonists Thymus Neoplasms Benzazepines Middle Aged medicine.disease Receptor antagonist Treatment Outcome Oncology Benzamides Quality of Life Female Hyponatremia business Biomarkers Antidiuretic medicine.drug |
| Zdroj: | Japanese journal of clinical oncology. 41(1) |
| ISSN: | 1465-3621 |
| Popis: | Ectopic antidiuretic hormone syndrome is a medical emergency characterized by dilutional hyponatremia. Clinical effectiveness of the vasopressin V2 receptor antagonist mozavaptan was evaluated in 16 patients. In short-term (7-day) treatment with the drug, serum sodium concentration (mean ± standard deviation) significantly (P = 0.002) increased from 122.8 ± 6.7 to 133.3 ± 8.3 mEq/l, and symptoms due to hyponatremia were improved. On the basis of these results, mozavaptan (Physuline(®)) was approved as an orphan drug for the treatment of the syndrome in 2006 in Japan. During the 43 months following its launch, 100 patients have been treated with the drug; overall clinical effects of the drug were found similar to those of this clinical trial. Clinically, mozavaptan may allow hyponatremic patients to be treated by aggressive cancer chemotherapy with platinum-containing drugs. Moreover, the drug may free patients from strict fluid-intake restrictions and thereby improve their quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|